Prognostic Significance of Moderate Cognitive Impairment in Patients at High and Very High Cardiovascular Risk

Nevrologiya, Neiropsikhiatriya, Psikhosomatika - Russian Federation
doi 10.14412/2074-2711-2019-4-33-37
Full Text
Abstract

Available in full text

Date
Authors
Publisher

IMA Press, LLC

Related search

Pcv74 - Cost-Effectiveness Analysis of Rosuvastatin Compared to Atorvastatin in Spanish Patients at Moderate, High, and Very High Cardiovascular Risk

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Cognitive Training for Very High Risk Incarcerated Adolescent Males

Frontiers in Psychiatry
PsychiatryMental Health
2020English

Preventive Counselling With the Use of Remote Technologies Provides Effective Control of Metabolic Risk Factors in Patients With High and Very High Cardiovascular Risk

Kardiologiya
Cardiovascular MedicineCardiology
2018English

Hypertriglyceridemia Is Associated With Long-Term Risk of Cardiovascular Events and Specific Comorbidity in Very High-Risk Hypertensive Patients

Ukrainian Biochemical Journal
Biochemistry
2020English

Physical Activity at Moderate and High Altitudes. Cardiovascular and Respiratory Morbidit

Arquivos Brasileiros de Cardiologia
Cardiovascular MedicineCardiology
1999English

Metabolic Effects of Ramadan Fasting in Patients at High Risk of Cardiovascular Diseases

International Journal of General Medicine
Medicine
2019English

GPla Polymorphisms Are Associated With Outcomes in Patients at High Cardiovascular Risk

Frontiers in Cardiovascular Medicine
Cardiovascular MedicineCardiology
2017English

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

New England Journal of Medicine
Medicine
2017English

Markers of Chronic Kidney Disease and Disorders of Renal Hemodynamics in Patients With Medically-Controlled Arterial Hypertension and High and Very High Cardiovascular Risk

Russian Journal of Cardiology
Cardiovascular MedicineCardiology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy